219 related articles for article (PubMed ID: 27432924)
1. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
Niedzwiecki D; Frankel WL; Venook AP; Ye X; Friedman PN; Goldberg RM; Mayer RJ; Colacchio TA; Mulligan JM; Davison TS; O'Brien E; Kerr P; Johnston PG; Kennedy RD; Harkin DP; Schilsky RL; Bertagnolli MM; Warren RS; Innocenti F
J Clin Oncol; 2016 Sep; 34(25):3047-53. PubMed ID: 27432924
[TBL] [Abstract][Full Text] [Related]
2. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
Venook AP; Niedzwiecki D; Lopatin M; Ye X; Lee M; Friedman PN; Frankel W; Clark-Langone K; Millward C; Shak S; Goldberg RM; Mahmoud NN; Warren RS; Schilsky RL; Bertagnolli MM
J Clin Oncol; 2013 May; 31(14):1775-81. PubMed ID: 23530100
[TBL] [Abstract][Full Text] [Related]
3. 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study.
Yamanaka T; Oki E; Yamazaki K; Yamaguchi K; Muro K; Uetake H; Sato T; Nishina T; Ikeda M; Kato T; Kanazawa A; Kusumoto T; Chao C; Lopatin M; Krishnakumar J; Bailey H; Akagi K; Ochiai A; Ohtsu A; Ohashi Y; Yoshino T
J Clin Oncol; 2016 Aug; 34(24):2906-13. PubMed ID: 27325854
[TBL] [Abstract][Full Text] [Related]
4. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
5. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
[TBL] [Abstract][Full Text] [Related]
6. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
Yothers G; O'Connell MJ; Lee M; Lopatin M; Clark-Langone KM; Millward C; Paik S; Sharif S; Shak S; Wolmark N
J Clin Oncol; 2013 Dec; 31(36):4512-9. PubMed ID: 24220557
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
8. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
[TBL] [Abstract][Full Text] [Related]
9. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.
Kennedy RD; Bylesjo M; Kerr P; Davison T; Black JM; Kay EW; Holt RJ; Proutski V; Ahdesmaki M; Farztdinov V; Goffard N; Hey P; McDyer F; Mulligan K; Mussen J; O'Brien E; Oliver G; Walker SM; Mulligan JM; Wilson C; Winter A; O'Donoghue D; Mulcahy H; O'Sullivan J; Sheahan K; Hyland J; Dhir R; Bathe OF; Winqvist O; Manne U; Shanmugam C; Ramaswamy S; Leon EJ; Smith WI; McDermott U; Wilson RH; Longley D; Marshall J; Cummins R; Sargent DJ; Johnston PG; Harkin DP
J Clin Oncol; 2011 Dec; 29(35):4620-6. PubMed ID: 22067406
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
11. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
Di Narzo AF; Tejpar S; Rossi S; Yan P; Popovici V; Wirapati P; Budinska E; Xie T; Estrella H; Pavlicek A; Mao M; Martin E; Scott W; Bosman FT; Roth A; Delorenzi M
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25246611
[TBL] [Abstract][Full Text] [Related]
12. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.
Niedzwiecki D; Bertagnolli MM; Warren RS; Compton CC; Kemeny NE; Benson AB; Eckhardt SG; Alberts S; Porjosh GN; Kerr DJ; Fields A; Rougier P; Pipas JM; Schwartz JH; Atkins J; O'Rourke M; Perry MC; Goldberg RM; Mayer RJ; Colacchio TA
J Clin Oncol; 2011 Aug; 29(23):3146-52. PubMed ID: 21747085
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
14. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
[TBL] [Abstract][Full Text] [Related]
15. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
16. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
[TBL] [Abstract][Full Text] [Related]
17. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
[TBL] [Abstract][Full Text] [Related]
18. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
[TBL] [Abstract][Full Text] [Related]
19. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Yothers G; Sargent DJ; Wolmark N; Goldberg RM; O'Connell MJ; Benedetti JK; Saltz LB; Dignam JJ; Blackstock AW;
J Natl Cancer Inst; 2011 Oct; 103(20):1498-506. PubMed ID: 21997132
[TBL] [Abstract][Full Text] [Related]
20. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Niedzwiecki D; Hasson RM; Lenz HJ; Ye C; Redston M; Ogino S; Fuchs CS; Compton CC; Mayer RJ; Goldberg RM; Colacchio TA; Saltz LB; Warren RS; Bertagnolli MM
Oncologist; 2017 Jan; 22(1):107-114. PubMed ID: 27821793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
